Transition of an androgen-dependent human prostate cancer cell line into an androgen-independent subline is associated with increased angiogenesis

Prostate

Volumn 62, Issue 4, 2005, Pages 364-373

  Gustavsson, Heléne ^a   Welén, Karin ^a   Damber, Jan Erik ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

LNCaP; Microvessel density; VEGF

Indexed keywords

ANDROGEN; PROSTATE SPECIFIC ANTIGEN; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CARCINOGENICITY; CASTRATION; CELL PROLIFERATION; CELL SECRETION; CELL STRAIN; CELL TRANSFORMATION; CONTROLLED STUDY; CULTURE MEDIUM; HORMONE ACTION; HORMONE DEPENDENCE; HUMAN; HUMAN CELL; MALE; MICROVASCULATURE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN SECRETION;

ANDROGENS; DRUG RESISTANCE, NEOPLASM; HUMANS; MALE; NEOVASCULARIZATION, PATHOLOGIC; PROSTATIC NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 13644262076     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/pros.20145     Document Type: Article

References (43)

1. Bruchovsky N, Rennie PS, Coldman AJ, Goldenberg SL, To M, Lawson D. Effects of androgen withdrawal on the stem cell composition of the Shionogi carcinoma. Cancer Res 1990;50(8): 2275-2282.
2. Isaacs JT, Coffey DS. Adaptation versus selection as the mechanism responsible for the relapse of prostatic cancer to androgen ablation therapy as studied in the Dunning R-3327-H adenocarcinoma. Cancer Res 1981;41(12 Pt 1):5070-5075.
3. Balk SP. Androgen receptor as a target in androgen-independent prostate cancer. Urology 2002;60:132-138.
4. Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, Vessella R, Rosenfeld MG, Sawyers CL. Molecular determinants of resistance to antiandrogen therapy. Nat Med 2004;10(1):33-39.
5. Nicholson B, Theodorescu D. Angiogenesis and prostate cancer rumor growth. J Cell Biochem 2004;91:125-150.
6. Jain RK, Safabakhsh N, Sckell A, Chen Y, Jiang P, Benjamin L, Yuan F, Keshet E. Endothelial cell death, angiogenesis, and microvascular function after castration in an androgen-dependent tumor: Role of vascular endothelial growth factor. Proc Natl Acad Sci USA 1998;95:10820-10825.
7. Folkman J. Is tissue mass regulated by vascular endothelial cells? Prostate as the first evidence. Endocrinology 1998;139:441-442.
8. Stewart RJ, Panigrahy D, Flynn E, Folkman J. Vascular endothelial growth factor expression and tumor angiogenesis are regulated by androgens in hormone responsive human prostate carcinoma: Evidence for androgen dependent destabilization of vascular endothelial growth factor transcripts. J Urol 2001;165:688-693.
9. Okihara K, Watanabe H, Kojima M. Kinetic study of rumor blood flow in prostatic cancer using power Doppler imaging. Ultrasound Med Biol 1999;25:89-94.
10. Benjamin LE, Golijanin D, Itin A, Pode D, Keshet E. Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J Clin Invest 1999;103(2):159-165.
11. Padhani AR, Gapinski CJ, Macvicar DA, Parker GJ, Suckling J, Revell PB, Leach MO, Dearnaley DP, Husband JE. Dynamic contrast enhanced MRI of prostate cancer: Correlation with morphology and tumour stage, histological grade, and PSA. Clin Radiol 2000;55:99-109.
12. Häggstrom S, Wikström P, Bergh A, Damber J-E. Expression of vascular endothelial growth factor and its receptor in the rat ventral prostate and Dunning R3327 PAP adenocarcinoma before and after castration. Prostate 1998;35(2):71-79.
13. Westin P, Stattin P, Damber J-E, Bergh A. Castration therapy rapidly induces apoptosis in a minority and decreases cell proliferation in a majority of human prostatic tumors. Am J Pathol 1995;146:1368-1375.
14. Stattin P, Westin P, Damber J-E, Bergh A. Short-term cellular effects induced by castration therapy in relation to clinical outcome in prostate cancer. Br J Cancer 1998;77:670-675.
15. Häggström S, Stattin P, Wikström P, Bergh A, Damber J-E. Castration-induced reduction of vascular endothelial growth factor expression in benign human prostate tissue is lost in advanced prostate cancer. BJU Int 2001;88(1):110-116.
16. Häggström S, Bergh A, Damber J-E. Vascular endothelial growth factor content in metastasizing and nonmetastasizing Dunning prostatic adenocarcinoma. Prostate 2000;45(1):42-50.
17. Jones A, Fujiyama C. Angiogenesis in urological malignancy: Prognostic indicator and therapeutic target. BJU Int 1999;83: 535-555.
18. Borre M, Offersen BV, Nerstrom B, Overgaard J. Microvessel density predicts survival in prostate cancer patients subjected to watchful waiting. Br J Cancer 1998;78:940-944.
19. Matsushima H, Goto T, Hosaka Y, Kitamura T, Kawabe K. Correlation between proliferation, apoptosis, and angiogenesis in prostate carcinoma and their relation to androgen ablation. Cancer 1999;85:1822-1827.
20. Lissbrant IF, Stattin P, Damber J-E, Bergh A. Vascular density is a predictor of cancer-specific survival in prostatic carcinoma. Prostate 1997;33:38-45.
21. Weidner N, Carroll PR, Flax J, Blumenfeld W, Folkman J. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol 1993;143(2):401-409.
22. Huss WJ, Hanrahan CF, Barrios RJ, Simons JW, Greenberg NM. Angiogenesis and prostate cancer: Identification of a molecular progression switch. Cancer Res 2001;61(6):2736-2743.
23. Connolly JM, Rose DP. Angiogenesis in two human prostate cancer cell lines with differing metastatic potential when growing as solid rumors in nude mice. J Urol 1998;160(3): 932-936.
24. Balbay MD, Pettaway CA, Kuniyasu H, Inoue K, Ramirez E, Li E, Fidler IJ, Dinney CP. Highly metastatic human prostate cancer growing within the prostate of athymic mice overexpress vascular endothelial growth factor. Clin Cancer Res 1999;5(4): 783-789.
25. West AF, O'Donnell M, Charlton RG, Neal DE, Leung HY. Correlation of vascular endothelial growth factor expression with fibroblast growth factor-8 expression and clinico-pathologic parameters in human prostate cancer. Br J Cancer 2001;85(4): 576-583.
26. Jackson MW, Bentel JM, Tilley WD. Vascular endothelial growth factor (VEGF) expression in prostate cancer and benign prostatic hyperplasia. J Urol 1997;157(6):2323-2328.
27. Doll JA, Reiher FK, Crawford SE, Pins MR, Campbell SC, Bouck NP. Thrombospondin-1, vascular endothelial growth factor and fibroblast growth factor-2 are key functional regulators of angiogenesis in the prostate. Prostate 2001;49(4):293-305.
28. Ferrer FA, Miller LJ, Andrawis RI, Kurtzman SH, Albertsen PC, Laudone VP, Kreutzer DL. Vascular endothelial growth factor (VEGF) expression in human prostate cancer: In situ and in vitro expression of VEGF by human prostate cancer cells. J Urol 1997;157(6):2329-2333.
29. Wilson MJ, Sinha AA. Human prostate rumor angiogenesis in nude mice: Metalloprotease and plasminogen activator activities during rumor growth and neovascularization of subcutaneously injected matrigel impregnated with human prostate rumor cells. Anat Rec 1997;249(1):63-73.
30. Papetti M, Herman IM. Mechanisms of normal and tumor-derived angiogenesis. Am J Physiol Cell Physiol 2002;282:C947-C970.
31. Alessandri G, Chirivi RG, Fiorentini S, Dossi R, Bonardelli S, Giulini SM, Zanetta G, Landoni F, Graziotti PP, Turano A, Caruso A, Zardi L, Giavazzi R, Bani MR. Phenotypic and functional characteristics of tumour-derived microvascular endothelial cells. Clin Exp Met 1999;17:655-662.
32. Igawa T, Lin F-F, Lee M-S, Karan D, Batra SK, Lin M-F. Establishment and characterization of androgen-independent human prostate cancer LNCaP cell model. Prostate 2002;50:222-235.
33. Härkönen P, Törn S, Kurkela R, Porvari K, Pulkka A, Lindfors A, Isomaa V, Vihko P. Sex hormone metabolism in prostate cancer cells during transition to an androgen-independent state. J Clin Endocrinol Metab 2003;88(2):705-712.
34. Hasenson M, Hartley-Asp B, Kihlfors C, Lundin A, Gustafsson J-Å, Pousette ÅHL. Effect of hormones on growth and ATP content of a human prostatic carcinoma cell line, LNCaP-r. Prostate 1985;7:183-194.
35. Gao M, Ossowski L, Ferrari AC. Activation of Rb and decline in androgen receptor protein precede retinoic acid-induced apoptosis in androgen-dependent LNCaP cells and their androgen-independent derivative. J Cell Physiol 1999;179(3):336-346.
36. Kokontis JM, Hay N, Liao S. Progression of LNCaP prostate tumor cells during androgen deprivation: Hormone-independent growth, repression of proliferation by androgen, and role for p27-kip-1 in androgen-induced cell cycle arrest. Mol Endocrinol 1998;12(7):941-953.
37. Lu S, Tsai SY, Tsai M-J. Molecular mechanisms of andrigen-independent growth of human prostate cancer LNCaP-AI cells. Endocrinoloy 1999;140(11):5054-5059.
38. Manni A, Bartholomew M, Caplan R, Boucher A, Santen R, Lipton A, Harvey H, Simmonds M, White-Hershey D, Gordon R. Androgen priming and chemotherapy in advanced prostate cancer: Evaluation of determinants of clinical outcome. J Clin Oncol 1988;6(9):1456-1466.
39. Horoszewicz JS, Leong SS, Kawinski E, Karr JP, Rosenthal H, Chu TM, Mirand EA, Murphy GP. LNCaP model of human prostatic carcinoma. Cancer Res 1983;43:1809-1818.
40. Hasenson M, Lundh B, Stege RH, Carlström KAM, Pousette AHL. PAP and PSA in prostatic carcinoma cell lines and aspiration biopsies: Relation to hormone sensitivity and to cytological grading. Prostate 1989;14(2):83-90.
41. Stege RH, Tribukait B, Carlström KAM, Grande M, Pousette AHL. Tissue PSA from fine-needle biopsies of prostatic carcinoma as related to serum PSA, clinical stage, cytological grade, and DNA ploidy. Prostate 1999;38(3):183-188.
42. Tso C-L, McBride WH, Sun J, Patel B, Tsui K-H, Paik SH, Gitlitz B, Caliliw R, Ophoven A, Wu L, deKernion J, Belldegrun A. Androgen deprivation induces selective outgrowth of aggressive hormone-refractory prostate cancer clones expressing distinct cellular and molecular properties not present in parental androgen-dependent cancer cells. Cancer J 2000;6:220-233.
43. Denmeade SR, Sokoll LJ, Dalrymple S, Rosen DM, Gady AM, Bruzek D, Ricklis RM, Isaacs JT. Dissocation between androgen responsiveness for malignant growth vs. expression of prostate specific differentiation markers PSA, hK2, and PSMA in human prostate cancer models. Prostate 2003;54:249-257.